Patents by Inventor Elisabeth Binder

Elisabeth Binder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS
    Publication number: 20150278438
    Abstract: The invention relates inter alia to methods for predicting the response of patients with depressive symptoms and/or anxiety symptoms to treatment with a CRHR1 antagonist, and algorithms, kits, microarrays, probes and or/primers for use in such methods.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 1, 2015
    Inventors: Bertram Müller-Myhsok, Elisabeth Binder, Florian Holsboer
  • Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments
    Patent number: 8030033
    Abstract: The present invention relates to methods, compositions and kits for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: October 4, 2011
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenshaften e.V.
    Inventors: Manfred Uhr, Florian Holsboer, Elisabeth Binder, Bertram Mueller-Myhsok
  • Method by Using Human or Mice-Isg12 to Develop and Prepare Drugs and Single Nucleotide Polymorphism in the Isg12 Gene for Diagnostic Use
    Publication number: 20080313751
    Abstract: Here is described a novel gene, the interferon inducible gene 12 (ISG12, IFI27), that interacts with nuclear receptors and enhances nuclear export of such transcription factors. As a consequence, the transcriptional activities of these nuclear receptors are decreased. As examples effects on NR4A1 and PPARa and PPARg are given. When ISG12 is absent as in ISG12 deficient mice transcriptional activities of these nuclear receptors are not impaired and their protective effects are fully appreciated. Consistently, ISG12 deficient mice are resistant to restenosis upon carotid artery ligation and to endotoxin induced death. Human genetics studies indicate the importance of ISG12 where the inventors could show a strong association between an intronic ISG12 SNP and the presence of hypercholesterolemia, diabetes type 2 and stroke. ISG12 is therefore a target for novel therapeutic strategies for the treatment of vascular diseases.
    Type: Application
    Filed: October 31, 2006
    Publication date: December 18, 2008
    Inventors: Nikolina Papac-Milicevic, Pavel Uhrin, Gernot Schabbauer, Elisabeth Binder, Bernd Binder
  • Polymorphisms in Abcb1 Associated with a Lack of Clinical Response to Medicaments
    Publication number: 20080064609
    Abstract: The present invention relates to methods, compositions and kits for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Application
    Filed: May 12, 2005
    Publication date: March 13, 2008
    Applicant: Max-Planck-Gesellschft Zur Foerderung Der Wissenschaften e.V.
    Inventors: Manfred Uhr, Florian Holsboer, Elisabeth Binder, Bertram Mueller-Myhsok
  • Novel Target for Antiderpressant Therapy
    Publication number: 20070298027
    Abstract: The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the invention provides a method of predicting the response to antidepressant therapy. Furthermore, a method of developing an anti-depressant drug, and pharmaceutical compositions are provided.
    Type: Application
    Filed: September 28, 2004
    Publication date: December 27, 2007
    Applicant: Max-Planck-Gesellschaft zur Forderung der Wissensc
    Inventors: Elisabeth Binder, Florian Holsboer, Theo Rein, Gabriele Wochnik, Bertram Muller-Myhsok, Manfred Uhr